Andrew Bowen

Innovation Manager at the University of Glasgow

📍 Greater Oxford Area, United Kingdom🔄 Updated September 2026💼 3 investments📅 17 years investing🗓 Last invested Jan 2024
VC🌍 United Kingdom
3
Total investments
2
Early stage
0
Mid stage
0
Late stage
17y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Dec 2016
EnzBond is an innovative start-up that aims to change the current understanding of biocatalysis. Here at EnzBond we have developed an automated In Silico platform that allows rapid optimization of enzymes used for the production of small molecules. Our proprietary technology allows us to drop the enzyme discovery cost >10x compared to the current market leaders and compress the discovery time to days.
early stageBiotechnology
Board Observer
Jan 2009
Recombinant protein expression - industry leading yield, quality and service Oxford Expression Technologies is a biotechnology company and centre of excellence for recombinant protein expression. We offer enhanced protein yield and quality coupled with top quality service. We offer a popular protein production service (baculoXPRESS) and a range of vectors for use in your own lab. We developed the patented flashBAC recombinant protein expression vectors, which are genetically optimised for improved protein production. We constantly innovate and are introducing new products and services, such as production of VLP vaccines and new cell lines for enhanced protein expression.
Experience · 4 entries
All (4)
Investments (3)
Board (3)
2024
Epigenetica Ltd
Board Observer
Jan 2024
2016
Board Observer
Dec 2016
EnzBond is an innovative start-up that aims to change the current understanding of biocatalysis. Here at EnzBond we have developed an automated In Silico platform that allows rapid optimization of enzymes used for the production of small molecules. Our proprietary technology allows us to drop the enzyme discovery cost >10x compared to the current market leaders and compress the discovery time to days.
early stageBiotechnology
2015
Senior Licensing and Ventures Manager
Nov 2015
Oxford University Innovation Limited is wholly owned by the University of Oxford. The company mission is to be the leading international technology transfer organisation, to transfer technology and expertise from the University of Oxford, to deliver value to all our clients, and to maximise social and economic benefits in a commercial manner. Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Our role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. We support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact.
2009
Board Observer
Jan 2009
Recombinant protein expression - industry leading yield, quality and service Oxford Expression Technologies is a biotechnology company and centre of excellence for recombinant protein expression. We offer enhanced protein yield and quality coupled with top quality service. We offer a popular protein production service (baculoXPRESS) and a range of vectors for use in your own lab. We developed the patented flashBAC recombinant protein expression vectors, which are genetically optimised for improved protein production. We constantly innovate and are introducing new products and services, such as production of VLP vaccines and new cell lines for enhanced protein expression.
Investment activity
2009–2024 · 3 investments
200912016120241
Recent (last 2 years)Earlier